Aims: Vascular endothelium is a major organ involved in hyperglycaemia and is affected by plasma asymmetric dimethylarginine (ADMA). ADMA is an endogenous, competitive inhibitor of nitric oxide synthase and is induced by inflammatory cytokines of tumour necrosis factor (TNF)-α in vitro. We hypothesized that a tight glycaemic control may restore endothelial function in patients with type-2 diabetes mellitus (DM), in association with modulation of TNF-α and/or reduction of ADMA level. Methods and results: In 24 patients with type-2 DM, the flow-mediated, endothelium-dependent dilation (FMD: %) of brachial arteries during reactive hyperaemia was determined by a high-resolution ultrasound method. Blood samples for glucose, cholesterol, TNF-α, and ADMA analyses were also collected from these patients after fasting. No significant glycaemic or FMD changes were observed in 10 patients receiving the conventional therapy. In 14 patients who were hospitalized and intensively treated, there was a significant decrease in glucose level after the treatment [from 190 ± 55 to 117 ± 21 (mean ± SD) mg/dL, P < 0.01]. After the intensive control of glucose level, FMD increased significantly (from 2.5 ± 0.9 to 7.2 ± 3.0%), accompanied by a significant (P < 0.01) decrease in TNF-α (from 29 ± 16 to 11 ± 9 pg/dL) and ADMA (from 4.8 ± 1.5 to 3.5 ± 1.1 μM/L) levels. The changes in FMD after treatment correlated inversely with those in TNF-α (R =-0.711, P < 0.01) and ADMA (R = -0.717, P < 0.01) levels. Conclusion: The intensive correction of hyperglycaemia is associated with the improvement of endothelial function, which is coupled with the decrease in the levels of reduction of plasma TNF-α and ADMA in patients with type-2 DM. A strict glycaemic control may exert anti-cytokine and anti-atherogenic effects and may therefore be pathophysiologically important.
- Diabetes mellitus
- Growth substances
- Nitric oxide
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine